Hsbc Holdings PLC Reduces Holdings in Omnicell, Inc. $OMCL

Posted by George Bondi on Jul 15th, 2026

Hsbc Holdings PLC lowered its stake in shares of Omnicell, Inc. (NASDAQ:OMCL – Free Report) by 48.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,417 shares of the company’s stock after selling 15,412 shares during the quarter. Hsbc Holdings PLC’s holdings in Omnicell were worth $748,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of OMCL. Mercer Global Advisors Inc. ADV grew its position in Omnicell by 51.2% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,573 shares of the company’s stock worth $615,000 after purchasing an additional 4,599 shares during the last quarter. State of Tennessee Department of Treasury raised its holdings in shares of Omnicell by 15.1% in the fourth quarter. State of Tennessee Department of Treasury now owns 26,504 shares of the company’s stock worth $1,285,000 after buying an additional 3,470 shares during the last quarter. EP Wealth Advisors LLC purchased a new position in shares of Omnicell in the fourth quarter worth $307,000. Fuller & Thaler Asset Management Inc. acquired a new stake in shares of Omnicell during the fourth quarter worth $610,000. Finally, Empowered Funds LLC acquired a new stake in shares of Omnicell during the fourth quarter worth $274,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on OMCL shares. Craig Hallum reissued a “buy” rating and issued a $55.00 target price on shares of Omnicell in a research report on Wednesday, April 29th. Wells Fargo & Company lifted their price target on Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a research report on Thursday, April 23rd. Zacks Research downgraded Omnicell from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Finally, Weiss Ratings raised Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Omnicell presently has an average rating of “Moderate Buy” and an average price target of $59.86.

Read Our Latest Report on Omnicell

Insider Buying and Selling at Omnicell

In other Omnicell news, EVP Corey J. Manley sold 5,025 shares of Omnicell stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the transaction, the executive vice president owned 112,783 shares in the company, valued at approximately $4,874,481.26. This trade represents a 4.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the transaction, the executive vice president directly owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. This trade represents a 1.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is currently owned by corporate insiders.

Omnicell Stock Performance

Shares of NASDAQ OMCL opened at $45.94 on Wednesday. The company has a 50 day simple moving average of $42.40 and a two-hundred day simple moving average of $41.50. The stock has a market cap of $2.09 billion, a price-to-earnings ratio of 104.41, a PEG ratio of 1.21 and a beta of 0.96. The company has a current ratio of 1.50, a quick ratio of 1.29 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 12 month low of $26.84 and a 12 month high of $55.00.

Omnicell (NASDAQ:OMCL – Get Free Report) last released its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The firm had revenue of $309.88 million for the quarter, compared to analyst estimates of $304.02 million. During the same quarter in the prior year, the business earned $0.26 earnings per share. The business’s quarterly revenue was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, analysts predict that Omnicell, Inc. will post 1.31 earnings per share for the current year.

Omnicell Profile

(Free Report)

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.